1. HOME

Biosimilars

Brand Name Image INN Therapeutic Areas Pharmac FundingMore information
NameHerzuma®
Herzuma®
INNTrastuzumab
IndicationsOncology
Pharmac Funding

Funded for:
- HER2 positive early breast cancer
- HER2 positive metastatic breast cancer
- HER2 positive advanced stomach cancer or gastro-oesophageal junction cancer 


See Pharmac website for more information.
Approved By Data Sheet Consumer Medicine Information (CMI) Herzuma webpage
NameRemsima® SC
Remsima® SC
INNInfliximab
IndicationsGastroenterology, Rheumatology, Dermatology
Pharmac Funding

Not Funded
Approved By Data Sheet Consumer Medicine Information (CMI)
NameYuflyma®
Yuflyma®
INNAdalimumab
IndicationsGastroenterology, Rheumatology, Dermatology
Pharmac Funding

Not Funded
Approved By Data Sheet Consumer Medicine Information (CMI)
NameVegzelma®
Vegzelma®
INNBevacizumab
IndicationsOncology
Pharmac Funding

Funded for: 
- recurrent respiratory papillomatosis
- ocular conditions
- unresectable hepatocellular carcinoma (liver cancer) 
- advanced ovarian cancer


See Pharmac website for more information.
Approved By Data Sheet Consumer Medicine Information (CMI) Vegzelma webpage
NameOmlyclo®
Omlyclo®
INNOmalizumab
IndicationsRespiratory, Dermatology
Pharmac Funding

Not Funded
Approved By


This product description is for medical and educational purposes only and not intended to promote the product.
For more details on the risks and benefits, please consult a doctor or healthcare professional.

For adverse events, product quality feedback or medical enquiries,
please contact Celltrion Healthcare New Zealand by emailing medinfo-nz@celltrionhc.com or calling 0800 838 899

INN, international non-proprietary name

Novel Therapeutics

Brand Name Image INN Therapeutic Areas Pharmac FundingMore information


This product description is for medical and educational purposes only and not intended to promote the product.
For more details on the risks and benefits, please consult a doctor or healthcare professional.

For adverse events, product quality feedback or medical enquiries,
please contact Celltrion Healthcare New Zealand by emailing medinfo-nz@celltrionhc.com or calling 0800 838 899

INN, international non-proprietary name

popup
You are leaving CelltrionHealthcare
New Zealand.

The Celltrion Healthcare Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local Celltrion Healthcare affiliate to obtain the appropriate product information for your country of residence.

The Celltrion Healthcare site that you have requested may be in a language that differs from your country of origin. The Celltrion Healthcare site that you have requested may not be optimized for your screen size.

Do you wish to leave this site?

We collect cookies

We use cookies to provide the services and features offered on our site and to improve the experience of our users. Cookies are data that are downloaded or stored on your computer or other device.

PRIVACY POLICY
▶ Essential cookies
Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.

▶ Analytics cookies

Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.